Randall Chase, AP Business Writer, On Wednesday April 21, 2010, 2:31 pm EDT WILMINGTON, Del. (AP) — A bankruptcy judge on Wednesday cleared the way for Washington Mutual Inc. shareholders to take legal action to force the company to hold a long overdue annual meeting. Ruling on a motion filed in Delaware by Washington Mutual’s [...]
Big Bear Mining Corp. Announces Addition of New Board Member, Renowned Geologist John Glasscock, of Cowboy Exploration
April 20th, 2010
Comments: 0
Press Release Source: Big Bear Mining Corp. On Tuesday April 20, 2010, 6:00 am EDT TEMPE, Ariz., April 20 /PRNewswire-FirstCall/ — Big Bear Mining is pleased to announce that Mr. John Glasscock has joined the board of directors. Mr. Glasscock is a geologist with over 25 years of experience in the mineral exploration industry including [...]
Globalequityreport.com announces Trading Alerts & Updates on the following Companies; ME, AEZS & ANDS
April 15th, 2010
Comments: 0
Mariner Energy (ME) will be acquired by independent energy company Apache Corp. for $2.7 billion to extend its deepwater projects in the Gulf of Mexico. Mariner’s deepwater portfolio includes nearly 100 blocks, seven discoveries in development and more than 50 prospects. AEterna Zentaris Inc. (AEZS) a late-stage drug development company specialized in oncology and endocrine [...]
After mining tragedy, no surrender by Massey CEO
April 7th, 2010
Comments: 0
(Fortune) — Don Blankenship, CEO of Massey Energy, has a lot of explaining to do this week. His company owns the Upper Big Branch Mine in Montcoal, W.Va., site of the most fatal mining disaster in decades. Even though the cause of Monday’s explosion, which claimed 25 lives, has yet to be determined, questions are [...]
ArQule (ARQL) Cancer Drug Shows Promise
March 31st, 2010
Comments: 0
(Reuters) – Biotechnology company ArQule Inc (ARQL.O) said its lead experimental lung cancer drug showed positive results in a mid-stage trial, sending its shares up to a new two-year high. The drug, ARQ 197, when used with another lung cancer drug, erlotinib, showed a 66 percent improvement in median progression-free survival (PFS) — the time [...]
